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ABSTRACT
BACKGROUND: Some patients who undergo 18F-FDG PET/CT 
for neoplastic or benign disease are also affected by diabetes or 
hyperglycaemia. We propose different preparation procedures in 
patients (pts) with hyperglycaemia (acute, temporary or chronic) 
or diabetes (type 1 or 2) at the time of the 18F-FDG injection, in 
order to improve the diagnostic scheduling of 18F-FDG PET/CT.
MATERIAL AND METHODS: We evaluated a sample of 13,063 
pts, examined in two different PET/CT centres, one with a station-
ary scanner (94.4%) and the other with a mobile device (5.6%). 
High blood sugar was present in 1,698 patients (13%) at the 
time of the 18F-FDG injection (hyperglycaemia was defined as 
fasting blood glucose > 11.1 mmol/l).
We considered all 18F-FDG PET/CT tests performed over a pe-
riod of 4 years (2006–2009). In the first 2 years (6,236 tests), 
scheduling was done directly by the administrative secretary. 
In the next two years, 6,827 pts underwent a preliminary visit 
to assess the test indications, medical history, and therapy as 
well as pre-test preparation.
We evaluated different preparation protocols for hyperglycaemic 
or diabetic pts, especially those recommended in the guidelines 
of the European Association of Nuclear Medicine (EANM) and 
Society of Nuclear Medicine (SNM). 
RESULTS: In the four-year period, 713/13,063 patients (5.45%) 
were rescheduled; of these, 78.8% were rescheduled in the two 
years before the implementation of our preparation protocols 
and 21.2% in the next two years. 
Before the implementation of our preparation protocols, 562 
patients (9%) presented occasional, acute or chronic hypergly-
caemia (56.7%), or diabetes (43.3%), requiring postponement 
of the test to a later date. The test was not performed in 17 
of 6,236 pts (0.27%) because of blood glucose levels above 
11.1 mmol/l for several days, while in 16/6236 pts (0.26%) the 
18F-FDG injection was performed despite high blood glucose 
levels, in view of the clinical urgency. 
After the implementation of the preparation protocols, 2.2% of 
pts were rescheduled because of occasional, acute or chronic 
hyperglycaemia (79%), or diabetes (21%); 0.1% of pts did not 
undergo the test because of chronic high blood glucose levels. 
Although the administration of insulin is recommended in the 
EANM and SNM guidelines, in our new preparation procedures 
experience it was not necessary, because we reduced the 
numbers of hyperglycaemic pts thanks to screening at the pre-
liminary visit and a subsequent good preparation of the patient 
before scheduling.
CONCLUSIONS: The application of our preparation protocols 
improves the on-time performance and diagnostic accuracy, 
and increases patients’ compliance. 
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Background
Several per cent of patients who undergo 18F-FDG PET/CT 
for neoplastic or benign disease are also affected by diabetes or 
hyperglycaemia. 18F-FDG, like glucose, is taken up by tumour 
cells via a sodium-independent facilitated diffusion [1]. The 
glucose transporter proteins are encoded by at least 7 different 
genes (GLUT1-GLUT7). Except for GLUT1, the glucose transpor-
ters genes are differently expressed according to the tissue. An 
intense uptake of 18F-FDG can suggest the presence of neoplastic 
cells, which produce energy primarily through anaerobic glyco-
lysis [2]. The mechanisms regulating glucose uptake in cancer 
cells have not been completely clariﬁ ed. Some authors have sug-
gested that 18F-FDG uptake may be impaired in diabetes and 
hyperglycaemia, due to direct competition between 18F-FDG and 
glucose for uptake by cancer cells [3]. 
Hyperglycaemia is deﬁ ned as fasting glycaemia levels higher 
than 7 mmol/l or a random plasma glucose ﬁ nding of >11.1 mmol/l. 
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High blood glucose levels are present in diabetic disease and in 
other conditions without speciﬁ c signs or symptoms. Certain medica-
tions increase the risk of hyperglycaemia, such as corticosteroids, 
cyclosporine, isoniazid, protease inhibitors, etc. [4, 5]. Chemotherapy 
drugs also induce high blood sugar, alter immune functions and 
cause severe side effects that can complicate the diagnosis [6].
Acute hyperglycaemia (blood glucose levels above 8 mmol/l 
— range 8 to 15 mmol/l), often present in uncontrolled diabetes or 
as a consequence of drug toxicity, is treated with insulin injections to 
avoid the failure of various organs.
Chronic hyperglycaemia is characterized by high blood glucose 
levels over a long period (> 7 mmol/l), causing damage to the blood 
vessels and to the organs they supply, leading to the complica-
tions of diabetes. Chronic hyperglycaemia can be measured via 
the HbA1c test. The most common causes of chronic hyperglycae-
mia are: diabetes mellitus, endocrinopathies, drugs that induce 
impaired insulin secretion, infections, and autoimmune disorders.
Diabetes mellitus is a group of metabolic diseases character-
ized by hyperglycaemia resulting from defects in insulin secretion, 
insulin action, or both. Diabetic patients present an increased 
incidence of atherosclerotic, cardiovascular, peripheral arterial, and 
cerebrovascular diseases that may be silent until major damage 
has been done [7], so many different new therapies are continu-
ally being proposed [8]. Hyperglycaemia, diabetes or anti-diabetic 
therapy may reduce the sensitivity of 18F-FDG PET/CT in the as-
sessment of malignancy [9]. Normally, the main patient preparation 
instructions for 18F-FDG PET/CT include fasting for at least 6 h 
prior to the start of the PET study, measuring the blood glucose 
level by a glucometer prior to administering FDG, then waiting for 
40 minutes before the test. Blood glucose should be less than 
11.1 mmol/l [10–12]. In case of higher blood glucose levels, many 
guidelines propose the administration of insulin [10], under the 
control of the endocrinologist.
Aim of the study
The aim of this work was to propose simple, different prepara-
tion procedures in patients with hyperglycaemia (acute, temporary 
or chronic) or diabetes (type 1 or 2) at the time of 18F-FDG injection, 
thus improving the diagnostic scheduling of stationary or mobile 
18F-FDG PET/CT facilities. 
The second endpoint was to evaluate how the application of 
rational preparation procedures improves the on-time performance 
and quality of the PET/CT exam.
Finally, the compliance of hyperglycaemic or diabetic pa-
tients who followed the preparation protocols was evaluated.
Material and methods
We evaluated a sample of 13,063 patients, examined at two 
different PET/CT centres, one with a stationary scanner (94.4%) 
and the other with a mobile device (5.6%). Hyperglycaemia (fasting 
blood glucose > 11.1 mmol/l) was present in 1,698 patients (13%) 
at the time of the 18F-FDG injection. Of these, 653 patients were 
insulin-dependent diabetics, 914 patients were non-insulin-depend-
ent diabetics treated with oral anti-diabetic drugs, 131 patients pre-
sented hyperglycaemia in the absence of diabetes (1% chronic 
hyperglycaemia and 0.4% temporary hyperglycaemia).
The 18F-FDG PET/CT tests performed over a period of 4 
years were analysed. In the ﬁ rst 2 years (6,236 tests), the scheduling 
was performed directly by the administrative secretary. In the next 
two years, 6,827  patients underwent a preliminary visit before the 
PET/CT to assess medical history, on-going treatments, to check 
the test indications and identify causes that could interfere with the 
18F-FDG PET/CT good quality.
We prescribed a different preparation protocol in patients with 
hyperglycaemia or diabetes.
Protocol for patients with hyperglycaemia
Non diabetic patients who presented with hyperglycaemia 
(> 11 mmol/l) on the day of the test were invited to sit in a warm 
waiting room, stay relaxed and drink plenty of ﬂ uids; blood glucose 
levels were measured every 20 minutes in the next three hours. If 
the glycaemia decreased below 11.1 mmol/l, we proceeded with 
the administration of 18F-FDG, otherwise the PET/CT test was post-
poned, and patients were advised to check daily fasting glycaemia 
in the morning for 5 days and to communicate these values to the 
nuclear medicine physician responsible for PET/CT. We resche-
duled the test when the glycaemia decreased. If the blood glucose 
levels remained persistently high, the nuclear medicine physician 
sent the rescheduled patients to a diabetologist for management 
of the glycaemic status by basal and nutritional insulin therapy. 
Protocol for patients with diabetes
The diabetic patients on oral antidiabetic drugs were asked to 
check their fasting blood glucose level in the morning for at least 7 
days before the 18F-FDG PET/CT, without any interruption of medi-
cation. For these patients, the 18F-FDG PET/CT was scheduled 
leaving an interval of at least 180 minutes between the administra-
tions of antidiabetic drugs and the administration of 18F-FDG.
Patients with insulin-dependent diabetes mellitus were asked 
to check their fasting blood glucose level in the morning for at 
least 5 days before the 18F-FDG PET/CT. We advised these pa-
tients to observe the following preparation protocol on the day of 
the test: breakfast at 6.30 AM with 1-2 bread rusks and a cup of 
tea without sugar, followed by a half-dose of the prescribed insu-
lin. The 18F-FDG PET/CT was scheduled in the late morning with 
an interval of 180-300 minutes between the insulin and 18F-FDG 
administrations.
Results
In the four-year period, 713/13063 (5.45%) patients were re-
scheduled. Of these, 562 patients (78.8%) were rescheduled in 
the two years before the implementation of our preparation proto-
cols and 151 patients (21.2%) in the next two years. 
Before the implementation of our preparation protocols, 
562/6236 patients (9%) presented occasional, acute or chronic 
hyperglycaemia (56.7%), or diabetes (43.3%), requiring postpone-
ment of the test. 
Seventeen of 6236 patients (0.27%) did not undergo the test 
because of blood glucose levels above 11.1 mmol/l for several days, 
whereas 16/6236 patients (0.26%) underwent the 18F-FDG injection 
despite high blood glucose, in view of the clinical urgency (Fig. 1A).
After the application of the preparation protocols, 151/6,827 
patients were rescheduled (2.2%), for occasional, acute or chronic 
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hyperglycaemia (79%), or diabetes (21%) (Fig. 2). Seven of 6,827 
patients (0.1%) did not undergo the test because of chronic high 
blood glucose (Fig. 1B) .
Discussion
There are few literature data about the inﬂ uence of diabe-
tes on the outcome of 18F-FDG PET/CT, and the results are 
sometimes contradictory. The issue is important because of the 
high prevalence of hyperglycaemia or diabetes in the population.
Until a few years ago, 18F-FDG PET/CT was not performed in 
patients with diabetes because of direct competition between high 
blood glucose levels and 18F-FDG. [3]. Blood glucose must also 
be considered in patients in whom 18F-FDG PET/CT is performed 
several times for the evaluation of chemotherapy or radiotherapy 
response [9].
Torizuka et al. compared the kinetics and the uptake of 18F-FDG 
in non-diabetic and diabetic patients and concluded that the 
uptake of 18F-FDG in patients with diabetes was less than in the 
non-diabetic control group [13]. Gorenberg et al. reported that the 
SUV was similar between diabetic and non-diabetic patients [14].
Acute hyperglycaemia is a factor known to decrease tumour 
uptake of 18F-FDG [15, 16] and increase uptake in the muscles [9], 
but these effects are demonstrated only by the oral loading glucose 
test [9, 17].
The effect of chronic hyperglycaemia on 18F-FDG PET/CT 
is controversial in the literature and there are even fewer data. 
Chronic hyperglycaemia has a similar effect to acute hyperglycae-
mia on muscle uptake, but a smaller effect on tumour uptake, which 
remains high and allows recognition of the lesions [18].
In patients with diabetes the diagnostic accuracy of 18F-FDG 
PET/CT is debated. Some authors do not recommend the perfor-
mance of 18F-FDG PET/CT [18], while others consider it reliable 
[18, 19].
The use of insulin has been proposed to regulate blood glucose 
in diabetic patients prior to 18F-FDG PET/CT. The appropriate use 
of insulin for the control of blood glucose increases the uptake ratio 
between tumour and normal tissue of the liver and lung but, on the 
contrary, it reduces the uptake ratio between tumour and muscle 
tissue [20]. Based on these data, the administration of insulin 
60 minutes before the 18F-FDG has been proposed as a means of 
reducing the blood glucose, without compromising the quality of 
the images or the SUV [21, 22]. 
The use of oral hypoglycaemic agents to prepare patients with 
hyperglycaemia or diabetes for 18F-FDG PET/CT is very limited. 
These drugs are used in insulin resistant patients. Oral hypogly-
caemic agents also have different effects on glucose metabolism in 
different tissues. It has been reported that glitazone has a powerful 
effect on increasing glucose uptake in skeletal muscle [23], while 
metformin reduces glucose production by the liver [24].
Metformin, due to its prolonged plasma half-life (15 hours), 
determines an increased 18F-FDG uptake in skeletal muscle and 
adipose tissue. Other authors have reported an increased 18F-FDG 
uptake also in the bowel, which may reduce the test sensitivity for 
recognizing cancerous lesions in the abdomen. It has therefore 
been recommended that metformin should be suspended at least 
12 hours prior to the 18F-FDG PET/CT [25]. Lin et al concluded that 
metformin and rosiglitazone do not affect the uptake of 18F-FDG. 
Medications that stimulate the secretion of insulin (tolbutamide) have 
a limited use as compared to other oral antidiabetics, inﬂ uence blood 
glucose by stimulating insulin secretion, and it may be appropriate to 
recommend their suspension before 18F-FDG PET/CT [29].
Fasting for 6 hours cannot be prescribed in diabetic patients, 
while for the execution of 18F-FDG PET/CT, blood glucose le-
vels below 11.1 mmol/l are required. Patients with higher glucose 
values cannot undergo the test because of the signiﬁ cant change 
in the biodistribution of 18F-FDG and the SUV reduction in tumour 
lesions [26].
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Figure 1. The results of scheduling of patients before and after our 
preparation protocols: the number of rescheduled patients decreased 
from 9% before the application of the preparation protocols (A) to 
2.2% after (B). No patients underwent 18F-FDG injections despite high 
blood glucose after the application of our preparation protocols
Figure 2. Rescheduled patients before and after our preparation 
protocols: the number of rescheduled diabetic patients reduced from 
43.3% before the application of our protocols to 21% after, while the 
number of rescheduled hyperglycaemic patients increased from 56.7% 
before to 79% after, caused by not fasting or corticosteroid drugs
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The American Society of Nuclear Medicine suggests the use of 
insulin before the administration of 18F-FDG in patients with glu-
cose values above 11.1 mmol/l. If the patient takes insulin therapy 
at home, the administration of 18F-FDG may need to be delayed 
according to the dose of insulin administered [10], in order to avoid 
an increased uptake in the myocardium, liver, muscles and adipose 
tissue. A negative effect of the use of insulin on tumour uptake 
has never been demonstrated. Insulin acts on GLUT4 transporters in 
the myocardium, striated muscle and adipose tissue, but has no 
effect on GLUT1 and GLUT 3 receptors in tumours [27].
In order to improve the reliability of the test and the quality of 
the images, some authors prescribe a high protein and low carbo-
hydrate diet in diabetic patients on the day before 18F-FDG PET/CT 
and abstention from nicotine and caffeine on the day of the test to 
reduce cardiac stimulation and consequently myocardial glucose 
uptake [28]. Currently, the preparation protocols for 18F-FDG 
PET/CT are determined by individual experience and a review of the 
literature. We evaluated different preparation protocols for hypergly-
caemic or diabetic patients, especially those recommended in the 
guidelines of European Association of Nuclear Medicine (EANM) 
and Society of Nuclear Medicine (SNM). The American guide-
lines considered mainly diabetic patients on insulin therapy [10].
The administration of insulin does not take into account the 
problem of hypoglycaemia on the day of the 18F-FDG PET/CT 
test. For this reason, we propose a protocol for the preparation of 
patients in the days before the 18F-FDG PET/CT test (blood glucose 
controls and half the insulin dose on the day of the test), direct 
contact with the nuclear physician and, if necessary, an interview 
with the diabetologist.
The 2003 EANM guidelines advised that blood glucose should 
be less than 7.22 mmol/l to perform the test and the not execusion 
of 18F-FDG PET/CT in patients with blood glucose values greater 
than 11.1 mmol/l [11]. Subsequently, in 2010, the EANM recom-
mended management of diabetic patients depending on the type of 
therapy. Particularly, for diabetic patients on oral therapy, 18F-FDG 
PET/CT is recommended preferably in the late morning with no 
therapy suspension. For patients on insulin therapy, preparation 
of the patient and a glycaemic control prior to the test is recom-
mended. These patients should eat a normal breakfast at 7 am, 
and then proceed with a normal amount of insulin injection, and 
18F-FDG PET/CT should be scheduled for the late morning [12].
In diabetic patients receiving oral antidiabetics our protocol, by 
leaving an interval of 180 minutes between the hypoglycaemic oral 
therapy and the 18F-FDG administration, reduced the diagnostic 
interference of these drugs on 18F-FDG uptake. 
The systematic application of the preparation protocols for 
18F-FDG PET/CT allowed us to reduce the number of test postpone-
ments (from 9% of patients before the application of the preparation 
protocols to 2.2% after), and the number of rescheduled diabetic 
patients (from 43.3% before to 21% after) (Fig. 3).
The increased number of hyperglycaemic patients observed 
(from 56.7% before to 79% after) was caused by not fasting or the 
use of corticosteroid drugs for fear of adverse reactions (Fig. 2).
Although recommended by EANM and SNM guidelines, in our 
experience the administration of insulin was not necessary, because 
the preliminary visit and a good preparation of the patient before 
scheduling was successful in reducing the numbers of patients pre-
senting with hyperglycaemia at the time of the test.
The protocols suggested by the guidelines are not al-
ways adaptable to diagnostic units with a stationary PET/CT 
scanner and much less so in those with a mobile device. In these, 
the PET/CT scanner may not be present on consecutive days, 
thus increasing the number of rescheduled patients or those who 
undergo 18F-FDG PET/CT despite high glucose values. Reducing 
the number of postponed tests also improved the assessment of 
the effectiveness of therapies (chemotherapy and radiotherapy). 
The waiting time between radiopharmaceutical administration and 
the PET/CT test has become more readily programmable and well 
accepted by patients. Finally, the reduction of rescheduled 18F-FDG 
PET/CT has also improved the operating costs of our PET/CT centre 
by increasing the number of 18F-FDG PET/CT tests performed 
daily and ensuring full use of the available radiopharmaceutical.
Figure 3. 18F-FDG PET/CT during follow-up in a patient with lung cancer. A. MIP showed no evidence of disease recurrence but increased uptake 
in the myocardium and muscles. At the time of 18F-FDG administration the patient had acute hyperglycemia (blood glucose > 11.1 mmol/l); 
B. 8 months later and after the application of our simple preparation protocols, MIP showed no evidence of disease recurrence and the best quality 
images. At the time of 18F-FDG administration the patient was euglycemic
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Conclusions
Two different protocols for hyperglycaemic and diabetic pa-
tients without the necessity of insulin administration were prepared. 
The protocols resulted well accepted by all patients. The applica-
tion of these preparation protocols improved the management of 
hyperglycaemic or diabetic patients and is adaptable to routine 
diagnostic centres with stationary or mobile devices.
A preliminary examination of patients with hyperglycaemia 
(acute or chronic) or diabetes (type 1 or 2) and the correct applica-
tion of the preparation protocols has reduced the number of the 
rescheduled patients. In short, the application of our preparation 
protocols improves the on-time performance, the diagnostic ac-
curacy and increases patient’s compliance.  
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